Why the study?
Does sacubitril/valsartan improve outcomes compared to ramipril in high-risk survivors of acute myocardial infarction?
Does sacubitril/valsartan improve outcomes compared to ramipril in high-risk survivors of acute myocardial infarction?
A post-hoc win-ratio analysis of the PARADISE-MI trial suggests sacubitril/valsartan is superior to ramipril in high-risk survivors of acute myocardial infarction when including investigator-identified events.
Answers are grounded in this paper and cite their sources.
Does not support switching from ramipril post-MI; leaves open sacubitril/valsartan superiority pending prospective confirmation.
In this post-hoc analysis of the PARADISE-MI trial using the win ratio and including investigator-identified events not having CEC confirmation, sacubitril/valsartan was superior to ramipril among high-risk survivors of acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Berwanger et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: